Company intelligence / Profile preview
Astrocyte Pharmaceuticals Inc.
- Ownership
- Private
- Development stage
- Phase 2
Overview
Astrocyte Pharmaceuticals has completed two Phase 1 safety trials in Europe involving 80 participants with no significant adverse effects or safety concerns. Their lead candidate AST-004 demonstrated significant efficacy in preclinical studies, including preserving up to 45% more brain tissue in a non-human primate model of stroke. The FDA has cleared their IND application for AST-004 for acute ischemic stroke, allowing them to proceed to Phase 2 clinical trials[8].
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Astrocyte Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Astrocyte Pharmaceuticals Inc..